Objective. The aim of our study was to research the engagement and personal contribution to volunteering of pharmaceutical professionals and students in conditions of Russian-Ukrainian war.
Methods. An anonymous online questionnaire-based survey was conducted among Ukrainian pharmaceutical professionals and students (n = 517; approximate response rate - 40%). e analyzed period was February-April 2023.
Statistical analysis was performed using a spreadsheet Microso Excel.
Results. The results of the questionnaire survey have shown that almost two thirds of respondents (63.45%) were engaged in volunteer activities. e most relevant sources of information about volunteering were pages, channels and
groups of volunteer organizations in social networks (22.21% of responses), information from friends, colleagues,
relatives, etc., related to volunteering (21.86%), various announcements in social networks (20.83%). Leaders among social networks were Telegram (28.32%), Instagram (28.05%) and Facebook (23.58%). The main motives for volunteering were the desire to help the army (43.57%) and internally displaced persons (25.73%), and the main forms of participation in volunteer activities were the collection of funds, clothes, household items, food and medicines (24.31%), transfer of funds for the needs of the army (17.36%) and for volunteer activities (17.26%).
Conclusion. The role of volunteering in the conditions of the Russian-Ukrainian war among pharmacists and pharmaceutical students was studied and understood.

Healthcare plays a crucial role in public and national safety as a significant part of state activity and a component of national safety, whose mission is to organize and ensure affordable medical care for the population. The four stages of the genesis of healthcare safety development with the corresponding safety models of formation were defined: technical, human factor or security management, systemic security management, and cognitive complexity. It was established that at all stages, little attention is paid to the issues of the formation of the pharmaceutical sector’s safety.
Taking into account the development of safety models that arise during the four stages of the genesis of safety science, we have proposed a model of the evolution of pharmaceutical safety formation.
At the same time, future research is proposed to focus on new holistic concepts of safety, such as “Safety II”, evaluation and validation methods, especially in the pharmaceutical sector, where the development of this topic remained in the second stage of the evolution of science, the search for pharmaceutical errors related to drugs.

My interest in specific nanomaterials and nanobiotechnologies for biology and medicine started in 2005, when a couple of my colleagues who are organic and physical chemists sent me a proposal to investigate the biological activities of their products in order to evaluate the potential biomedical applications of the synthe-sized products. The role of my department at the Institute of Cell Biology, NAS of Ukraine, was to study the possibility of using new products, organic polymers and C60-fullerene nanoparticles, as platforms for drug and gene delivery. The need for such platforms exists because of the inaction of many medicines and their adverse effects in the treated organism. In addition, the physicochemical properties of many drugs, for example, with their poor water solubility, do not allow for a convenient application of these drugs. As a result of the realization of joint research projects with my colleagues working in Eastern and Central European countries, several nanoplatforms were developed for drug and gene delivery. Thus, there was a need
for the analysis and summarization of our experience in the molecular design, chemical synthesis, and biomedical application of novel nanomaterials in order to pass that experience to other scientists who work in this rapidly developing field of materials science. Most co-authors of this book participated in the TechConnect World Innovation Conference in Washington, DC (USA), in 2017. Their oral and poster presentations were visited by Merry Stuber, Senior Editor with Springer Nature Publishers. She asked Dr. Sandor Vari, Director of International Research and Innovation in Medicine Program (Cedars-Sinai Medical Center, Los Angeles, CA, USA) and RECOOP Association (https://www.cedars-sinai.org/research/administration/recoop.html), who managed our participation at the TechConnect World Innovation Conference, if he would prepare a book devoted to our results in the development of novel nanomaterials and nanobiotechnologies for biomedical use. This initiative was interrupted by COVID-19-related problems, but finally, we can present our
book to readers. The logistics of composing the presented materials is based on offering to read-ers a unique manual for their strategy for developing their own nanomaterials for biomedical applications, starting from their molecular design and synthesis, and moving to necessary steps of their physical-chemical and toxicological characteris-tics (biodegradability, biocompatibility, controlled delivery and clearance in the organism, as well as potential bio-risks for the environment). Both the organic (novel surface-active comb-like PEG-containing polymers) and mineral (novel water-soluble C60-fullerene-based nanoplatforms and magnetic iron oxide-based nano- and micro-particles for theranostics) materials used in biomedical applica-tions are described by the leading specialists in the corresponding fields. The nano-toxicology-related aspects of these and other biomedical materials are described
both in general, including genotoxicity and environmental toxicity, and specifically, hepato-, cardio-, nephro-, and immune-toxicities. Environmental aspects of the application of various nanomaterials have been characterized for freshwater and marine organisms, as well as for the multipollutant strategy of assessment of the environmental quality and health risks caused by air nano-pollutants. Bioimaging of nanomaterials is a central element for monitoring their biological action, and this aspect is described in the book as characterization of novel polymeric nanocarriers for gene delivery, which is a crucial step in gene therapy that is considered to be the future of medicine. The co-authors of all chapters of this book are thankful to the people who initi-
ated its writing, as well as to numerous members of the research teams who assisted in the experiments aimed at the development of novel nanomaterials and nanobio-technologies for biomedical applications.

Introduction. Epilepsy, as a chronic non-infectious disease of the brain, affects according to some data about 50 million, according to others - about 65 million people worldwide. Epilepsy can be treated with antiepileptic drugs (AEDs), diet therapy, and surgery. AEDs are drugs of various origin, which are used to prevent or reduce (in intensity and frequency) seizures, their corresponding equivalents (loss or disturbance of consciousness, behavioral and autonomic disorders, etc.), which are observed during periodically occurring attacks of various forms of epilepsy. The peculiarity of the treatment of epilepsy is the need for regular daily intake of AEDs for many years, including at least 3-5 years after the cessation of seizures. The number of patients forced to take AEDs during whole life reaches 15%. Material & methods. The sources of information were: domestic and foreign web resources, the State Register of Medicines of Ukraine (for searching of AEDs) (as of February 1, 2023), registers of drugs which are subjects to reimbursement under the medical guarantee program. The several methods were used in the research, such as: information search, comparison, analysis, generalization, marketing.  Results & discussion. The analytical study of AEDs showed that in Ukraine as of February 1, 2023, were registered 325 trade names (TN) of AEDs, which represented 16 international non-propriatory names (INN). About half (48.85%) of the researched assortment is made by pregabalin-based medicines. Almost one-eighth parts of the assortment (12.92% each) is taken by lamotrigine and levitiracetam TN. In total, drugs of these three INNs make up about 72% of the nomenclature of AEDs. The distribution of the studied assortment by dosage forms type showed that the absolute majority of AEDs was represented by capsules (51.08%) and tablets (45.23%).  It was established that three-quarters (75.38%) of the nomenclature of AEDs are drugs of foreign production. They are represented by 65 companies from 23 countries of the world. Among them, the vast majority (88.57%) are produced by one company, a tenth part (10.20 %) – by two-three manufacturers, and three TN of Pregabalin euro (1.22 %) – by 13 enterprises. As for domestic medicines, they are represented by 13 manufacturers, and 9 out of 10 (93.75%) of their products are made by one, and the rest by two companies. High production activity regarding AEDs is characteristic of enterprises from India (16.67% of manufacturers, Index of Production Activity (IPA) = 26.28%) and Ukraine (16.67% of manufacturers, IPA = 22.96%). Among foreign enterprises, the highest production activity has Dr. Reddy's Laboratories Limited, India (IPA = 6.63%), and among Ukrainian manufacturers - LLC "Pharma Start" (IPA = 3.83%). As a result of the data analysis of 5 Registers of medicines, the prices of which are subject to reimbursement under the program of state guarantee program of medical care of the population for 2021-2023, an increase in the number of AEDs INN from 3 to 4 was found. The analysis of the latest Register as of August 10, 2023 showed that it included 31 TN of these drugs (lamotrigine – 18, carbamazepine – 10, valproic acid – 2 and phenytoin – 1). At the same time, patients with epilepsy can receive 10 medicines free of charge, with a surcharge of up to 10% of the cost - 1 medicine, with a surcharge of 10-20% - 4 medicines, 21-30% - 10 medicines, 31-40% - 2 medicines and in within 41-50% - 4 medicines. Conclusion.  Separate components of the marketing complex regarding antiepileptic drugs registered in Ukraine and their role in the context of the program of state guarantee program of medical care of the population were studied.

In terms of the novel coronavirus disease, the issues of human rights, namely those of healthcare provider and the patient, are of great interest in different states. Considering the existence of the legislative controversies and loopholes in the said area in Ukraine, the objective of the article aims to outline the procedure of personal data processing in the conditions of COVID-19, according to the legislation of Ukraine, to identify problematic issues and search for ways to solve them, to analyze the experience of foreign countries to clarify best state practices and to cover the right to privacy about the state of health, ascertaining whether there are any changes regarding the performance of the professional duty to maintain medical secrecy in conditions of the pandemic. The article outlines foreign practices on restricting human rights to privacy and reveals a balance with public health interests, according to the European Court of Human Rights